Seven Solutions for Neuroprotection in Parkinson's Disease - Université de Lille Accéder directement au contenu
Article Dans Une Revue Movement Disorders Année : 2021

Seven Solutions for Neuroprotection in Parkinson's Disease


Parkinson's disease (PD) is a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra and accumulation of iron and alpha-synuclein; it follows a characteristic pattern throughout the nervous system. Despite decades of successful preclinical neuroprotective studies, no drug has then shown efficacy in clinical trials. Considering this dilemma, we have reviewed and organized solutions of varying importance that can be exclusive or additive, and we outline approaches to help generate successful development of neuroprotective drugs for PD: (1) select patients in which the targeted mechanism is involved in the pathological process associated with the monitoring of target engagement, (2) combine treatments that target multiple pathways, (3) establish earliest interventions and develop better prodromal biomarkers, (4) adopt rigorous methodology and specific disease-relevant designs for disease-modifying clinical trials, (5) customize drug with better brain biodistribution, (6) prioritize repurposed drugs as a first line approach, and (7) adapt preclinical models to the targeted mechanisms with translational biomarkers to increase their predictive value. © 2020 International Parkinson and Movement Disorder Society


Fichier principal
Vignette du fichier
MDS-20-1261.R1_Proof_hi.pdf (825.19 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03261732 , version 1 (16-06-2021)



David Devos, Etienne Hirsch, Richard Wyse. Seven Solutions for Neuroprotection in Parkinson's Disease. Movement Disorders, 2021, 36 (2), pp.306-316. ⟨10.1002/mds.28379⟩. ⟨hal-03261732⟩
28 Consultations
589 Téléchargements



Gmail Mastodon Facebook X LinkedIn More